Get the Stockscreener App
4.51
3.43%
-0.16
Rxsight Inc stock is traded at $4.51, with a volume of 1.04M.
It is down -3.43% in the last 24 hours and down -16.48% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$4.67
Open:
$4.7
24h Volume:
1.04M
Relative Volume:
1.40
Market Cap:
$187.59M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-4.7304
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
-6.24%
1M Performance:
-16.48%
6M Performance:
-38.89%
1Y Performance:
-46.82%
1-Day Range:
$4.495
$4.83
1-Week Range:
$4.40
$4.98
52-Week Range:
$4.40
$13.22
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.51 | 187.59M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
RxSight, Inc. (RXST) insider now holds 235,516 shares after option exercise - Stock Titan
The Technical Signals Behind (RXST) That Institutions Follow - Stock Traders Daily
Alcon, RxSight Form Collaboration to Develop Adjustable PCIOLs - Medical Product Outsourcing
RxSight (NASDAQ: RXST) CFO swaps 258K options, cuts strike to $6.375 with no share change - Stock Titan
RxSight (NASDAQ: RXST) COO swaps high-priced options for new $6.375 grants - Stock Titan
RxSight (RXST) CMO exchanges higher-priced options for new $6.375 grants - Stock Titan
RxSight (NASDAQ:RXST) Faces a Crucial Test on the Road to Scale - Kalkine Media
RxSight at wells fargo healthcare conference: reset centers on LAL growth - Investing.com Canada
RxSight at wells fargo healthcare conference: reset centers on LAL growth - Investing.com India
RxSight at wells fargo healthcare conference: reset centers on LAL growth - Investing.com UK
RxSight (RXST) resets exec stock options to $6.375 - Stock Titan
RxSight (RXST) ends employee option swap after 91.9% take-up - Stock Titan
RXST Form 4 FilingsRxSight, Inc. SEC Form 4 - Stock Titan
RXST stock slips as insider selling and cash level draw attention - AD HOC NEWS
RxSight Officer Mark Wilterding to Sell 7,765 Shares Worth $54,044.40 to Cover Tax Withholding - Kalkine Media
RxSight stock edges higher after insider tax sales and Q2 beat - ad-hoc-news.de
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com - Investing.com South Africa
RxSight COO Ilya Goldshleger sells $14,205 in company stock By Investing.com - Investing.com South Africa
RxSight COO Ilya Goldshleger sells $14,205 in company stock By Investing.com - Investing.com Australia
RxSight CMO Ronald Kurtz sells $35,496 in shares for tax By Investing.com - Investing.com Australia
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com - Investing.com Canada
RxSight CFO Mark Wilterding sells $54,044 in company stock - Investing.com
RxSight COO Ilya Goldshleger sells $14,205 in company stock - Investing.com
RxSight CMO Ronald Kurtz sells $35,496 in shares for tax By Investing.com - Investing.com Canada
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com - Investing.com Nigeria
RxSight CMO Ronald Kurtz sells $35,496 in shares for tax - Investing.com India
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com - Investing.com UK
RxSight chief business development officer Eric Weinberg sells $14,205 in stock - Investing.com
RxSight chief business development officer Eric Weinberg sells $14,205 in stock - Investing.com Canada
RxSight chief business development officer Eric Weinberg sells $14,205 in stock - Investing.com India
RxSight (NASDAQ: RXST) officer plans 5,100-share sale to cover taxes - Stock Titan
RSU vesting at RxSight (NASDAQ: RXST) prompts insider share sale - Stock Titan
RxSight (RXST) officer to sell shares for taxes - Stock Titan
RxSight (RXST) CFO sells shares to cover RSU taxes - Stock Titan
RxSight (RXST) CMO vests 13,425 units, sells shares for taxes - Stock Titan
RxSight (RXST) COO sells 2,041 shares after RSU vest - Stock Titan
RxSight (RXST) exec’s stock sale only covers taxes - Stock Titan
Price to earnings forward of RxSight, Inc. – NASDAQ:RXST - TradingView
(RXST) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RxSight (RXST) officer to sell 5,370 shares for RSU taxes - Stock Titan
RxSight stock holds in the lower single digits as losses narrow on stronger quarterly revenue - ad-hoc-news.de
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference - Yahoo Finance
RxSight (NASDAQ: RXST) refreshes documents for option exchange - Stock Titan
Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST - MarketBeat
Steven Cohen’s Point72 discloses RxSight (RXST) stake - Stock Titan
RxSight (RXST) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; Price Move - vinanet.vn
RxSight (RXST) Market: Moves 1.88% Higher to $6.49 in the Current Update; Boundary Watch: Support at $6.17 and Resistance at $6.81 Frame the Range on the DayATR Trailing Stop - vinanet.vn
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight (RXST) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Price Reaction: The Stock Ends Down 1.70% in the Latest SessionGuidance Upgrade Report - Vinanet
RxSight (NASDAQ: RXST) ex-director to sell 11,890 shares - Stock Titan
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rxsight Inc Stock (RXST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weinberg Eric | See remarks |
Sep 02 '26 |
Sale |
6.96 |
2,041 |
14,205 |
200,348 |
| Kurtz Ronald M MD | Officer |
Sep 02 '26 |
Proposed Sale |
6.96 |
5,100 |
35,496 |
0 |
| Wilterding Mark | Officer |
Sep 02 '26 |
Proposed Sale |
6.96 |
7,765 |
54,044 |
0 |
| Goldshleger Ilya | Officer |
Sep 02 '26 |
Proposed Sale |
6.96 |
2,041 |
14,205 |
0 |
| Weinberg Eric | Officer |
Sep 02 '26 |
Proposed Sale |
6.96 |
2,041 |
14,205 |
0 |
| Kurtz Ronald M MD | Chief Medical Officer |
Sep 02 '26 |
Sale |
6.96 |
5,100 |
35,496 |
71,775 |
| Wilterding Mark | Chief Financial Officer |
Sep 02 '26 |
Sale |
6.96 |
7,765 |
54,044 |
25,049 |
| Goldshleger Ilya | Chief Operating Officer |
Sep 02 '26 |
Sale |
6.96 |
2,041 |
14,205 |
81,509 |
| RAYMOND W COHEN | Former Director |
Aug 18 '26 |
Proposed Sale |
6.37 |
11,890 |
75,749 |
0 |
| Goldshleger Ilya | Chief Operating Officer |
Apr 17 '26 |
Option Exercise |
4.13 |
12,489 |
51,580 |
78,180 |
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):